Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)
A Multicenter Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study With Three Fixed Doses of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)
Sponsor: Otsuka America Pharmaceutical
Listed as NCT00337571, this PHASE3 trial focuses on Autistic Disorder and Behavioral Symptoms and remains completed. Sponsored by Otsuka America Pharmaceutical, it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jun 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Otsuka America Pharmaceutical
- Otsuka Pharmaceutical Development & Commercialization, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Asheville, United States, Aurora, United States, Bethpage, United States, Birmingham, United States, Boca Raton, United States, Bothell, United States, Chicago, United States, Columbus, United States, Dallas, United States, Detroit, United States and 21 more location s